What is the Future of PD-L1 Inhibitors in Cancer Treatment?
The future of PD-L1 inhibitors looks promising, with ongoing research focusing on combination therapies that may enhance their efficacy. Trials are investigating combinations with chemotherapy, other immunotherapies, and targeted therapies to improve outcomes. Personalized medicine approaches are also being explored to identify patients most likely to benefit from PD-L1 inhibitors based on genetic and molecular tumor profiles.
